Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 11/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059506 | 0.82 | NR1H2 (0.50) | NR1H2 | |
| SCHEMBL30189906 | 0.82 | NR1H2 (0.50) | NR1H2 | |
| SCHEMBL6695093 | 0.79 | ITK (0.39) | NR1H2 | |
| SCHEMBL1256058 | 0.78 | KMT2A (0.41) | MCL1DAO | |
| SCHEMBL8801877 | 0.75 | TLR8 (0.47) | TP53TSHR | |
| SCHEMBL7243871 | 0.75 | CA12 (0.44) | NOD2NOD1AGTR1TP53TSHR | |
| SCHEMBL8801615 | 0.74 | HTR4 (0.37) | OXER1 | |
| SCHEMBL4721470 | 0.74 | OXER1 (0.32) | OXER1 | |
| SCHEMBL8802333 | 0.73 | TLR8 (0.49) | TP53 | |
| SCHEMBL7551690 | 0.72 | OXER1 (0.59) | OXER1MCL1NOD2NOD1AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167115-A1 | Antiviral Agents, Uses Thereof and Methods for Their Preparation | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-06-01 | — | — | US | disclosed |
| EP-4139307-A1 | ANTIVIRAL AGENTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | The University of British Columbia (CA) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021212234-A1 | ANTIVIRAL AGENTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-10-28 | — | — | WO | disclosed |
| WO-2011121629-A1 | INDOLIC DERIVATIVES AND USE THEREOF IN MEDICAL FIELD | UNIVERSITA' DEGLI STUDI DL ROMA "LA SAPIENZA" (IT) | 2011-10-06 | — | — | WO | disclosed |
| US-7291732-B2 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20050107458-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-6872746-B2 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1088823-B1 | Fused pyrrolocarbazoles | CEPHALON INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1206473-B1 | ISOMERIC FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | CEPHALON INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030216419-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. | 2003-11-20 | — | — | US | disclosed |
| US-5705511-A | ENZYME INHIBITORS, ANTIINFLAMMATORY, TROPHIC FACTOR, ANTICANCER CELL GROWTH | CEPHALON, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997031002-A9 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997031002-A1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0785938-A1 | FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5616724-A | FOR POTENTIATION OF HUMAN INTERFERON-GAMMA; IMMUNOLOGY | CEPHALON, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1997010825-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
| US-5594009-A | KINASE INHIBITORS, TROPHIC FACTOR-INDUCED ACTIVITY ENHANCEMENT, CELL SURVIVAL | CEPHALON, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5591855-A | KINASE INHIBITORS, TROPHIC FACTOR-INDUCED ACTIVITY ENHANCEMENT, CELL SURVIVAL | CEPHALON, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| US-5475110-A | Treating nervous system disorders and inflammation, inhibiting protein and tyrosine kinases, inhibiting cell growth | CEPHALON, INC. (US) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216419-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | PIN1, QPCT, PAICS | OXER1 1919/4885MCL1 573/4885NOD2 433/4885 |
| US-20230167115-A1 | Antiviral Agents, Uses Thereof and Methods for Their Preparation | SARS1, ZC3HAV1, EIF2AK2 | OXER1 4590/4885MCL1 718/4885NOD2 1619/4885 |
| US-20050107458-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | PIN1, QPCT, PAICS | OXER1 1919/4885MCL1 573/4885NOD2 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.